OSUR at a glance
ORASURE TECHNOLOGIES INC (OSUR, SEC CIK 1116463) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ORASURE TECHNOLOGIES INC (OSUR) reported revenue of $115.0 million (down 38.1% from FY2024) and a net loss of $68.7 million. Diluted EPS was -$0.94.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ORASURE TECHNOLOGIES INC (OSUR) shares worth $82.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Boyd Steven Kyle on May 14, 2026 of 25,000 shares at $2.99 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $115.0M
- −38.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $82.7M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Form 10-K
- Carried-forward risks include regulatory compliance, product competition, operational execution, and financial liquidity exposures
Management Discussion & Analysis
- Q3 revenue $30.9M, up 14% from $27.1M YoY
- Gross margin 45.2% vs 43.5% YoY; operating loss $13.0M vs $16.1M
- Best segment: Sample Management Solutions, $12.5M, up 21% from $10.3M
- Cash $148.2M vs $199.3M at December 31, 2025; operating cash use $34.7M
- Capital deployment: $5.0M investing outflow, $8.6M financing outflow including $7.0M stock repurchases
AI summary of the OSUR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- OraSure announced consolidated results for the quarter ended September 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $30.9M, up 14% year over year, led by Diagnostics growth of 16% and Sample Management Solutions growth of 21%
- GAAP gross margin expanded to 45.2% from 43.5%, reflecting operational efficiencies and improved fixed-cost absorption
Item EX-99.1: Item EX-99.1
- Q2 revenue $30.6M, down 2% YoY but up 9.7% sequentially, exceeding guidance and signaling early recovery
- Diagnostics revenue $19.4M, up 1% YoY, while COVID-19 revenue fell 96% to $1,000 and risk-assessment revenue ended
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
- Consolidated financial details and management commentary contained in Exhibit 99.1 press release
Item 8.01: Other Events
- FDA clearance expands Colli-Pee™ Dx use with Roche STI tests for four infections
- Compatibility covers Roche cobas 5800, 6800, and 8800 molecular diagnostic systems
AI summaries of OSUR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OSUR
Don't miss the next OSUR filing
- Alerts as it files. A push when OSUR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OSUR, by share count.
- Ask anything. An AI agent that reads every OSUR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boyd Steven Kyle | A | Sep 29, 2026 | 4,797 | $3.88 |
| Kenny John P. | F | Sep 6, 2026 | 5,116 | $3.43 |
| Boyd Steven Kyle | A | Jun 26, 2026 | 3,666 | $4.43 |
| Boyd Steven Kyle | A | Jun 3, 2026 | 46,106 | - |
| Kenny John P. | A | Jun 3, 2026 | 46,106 | - |
| McMahon Robert W. | A | Jun 3, 2026 | 46,106 | - |
| Gagliano Nancy J | A | Jun 3, 2026 | 46,106 | - |
| Marmora Lelio | A | Jun 3, 2026 | 46,106 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $185.8M | $115.0M |
| Gross Profit | - | $79.4M | $48.2M |
| Operating Income | - | -$28.3M | -$72.0M |
| Net Income | - | -$19.5M | -$68.7M |
| Gross Margin | - | 42.7% | 41.9% |
| Op. Margin | - | -15.2% | -62.6% |
| Net Margin | - | -10.5% | -59.8% |
| Balance Sheet | |||
| Total Assets | $482.8M | $479.7M | $403.2M |
| Equity | $430.7M | $410.3M | $340.8M |
| ROE | - | -4.8% | -20.2% |
| Per Share | |||
| EPS | - | $-0.26 | $-0.94 |
| Cash Flow | |||
| Operating CF | - | $27.4M | -$49.0M |
| CapEx | - | $3.8M | $4.2M |
Source: XBRL data in ORASURE TECHNOLOGIES INC (OSUR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OSUR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $82.7M |
| Q2 2026 | 26 | $95.1M |
| Q1 2026 | 26 | $66.5M |
| Q4 2025 | 22 | $59.0M |
| Q3 2025 | 24 | $93.3M |
| Q2 2025 | 27 | $81.5M |
| Q1 2025 | 25 | $77.4M |
| Q4 2024 | 22 | $76.0M |
- Bank of America Corp+532.6K (+928%)
- Morgan Stanley+58.6K (+17%)
- Goldman Sachs Group+50.0K (+9%)
- Invesco Ltd+41.7K (+31%)
- JPMorgan Chase & Co+32.5K (+6%)
- BlackRock−183.1K (-3%)
- Millennium Management−145.9K (-77%)
- D.E. Shaw & Co−123.5K (-15%)
- Vanguard Capital Management LLC−118.7K (-4%)
- Dimensional Fund Advisors−85.4K (-4%)
- Franklin Resources+36.4K
- FMR LLC (Fidelity)−10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OSUR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| SC 13D | Sep 17, 2026 | - | - | |
| 4 | Sep 9, 2026 | - | - | - |
| SC 13G | Aug 12, 2026 | - | - | |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| SC 13G | Apr 30, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
OSUR SEC filings: frequently asked questions
Which institutions hold OSUR stock?
As of September 30, 2026, the largest ORASURE TECHNOLOGIES INC (OSUR) holders among the 13F filers tracked by SignalX were BlackRock ($23.8 million), Vanguard Capital Management LLC ($11.4 million), Dimensional Fund Advisors ($8.8 million), Renaissance Technologies LLC ($7.7 million), State Street Corp ($6.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OSUR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ORASURE TECHNOLOGIES INC (OSUR) reported revenue of $115.0 million (down 38.1% from FY2024) and a net loss of $68.7 million. Diluted EPS was -$0.94. The figures come from the XBRL data in the 10-K.
What did OSUR report in its latest 8-K?
ORASURE TECHNOLOGIES INC (OSUR) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). OraSure announced consolidated results for the quarter ended September 30, 2026.
What are the latest OSUR SEC filings?
ORASURE TECHNOLOGIES INC (OSUR) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 1, 2026.
What is OSUR's SEC CIK number?
ORASURE TECHNOLOGIES INC (OSUR)'s SEC Central Index Key (CIK) is 1116463. EDGAR lists every OSUR filing under that number.
Ask anything about OSUR
The research agent reads OSUR's filings, financials, insider trades and 13F holders, then answers with sources.